This federal Project Grant award, valued at $782,362, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research conducted by the University of California, Los Angeles (UCLA) to investigate the role of TREK-1 potassium channels in acute respiratory distress syndrome (ARDS).
Specifically, the research aims to determine if ARDS decreases epithelial and endothelial TREK-1 levels, leading to cell membrane depolarization and calcium-dependent inflammation. The project will also evaluate whether activating the residual TREK-1 channels can protect against ARDS induced by influenza A virus, hyperoxia, and mechanical ventilation. The research will utilize novel pharmacological and genetic approaches, as well as next-generation experimental ARDS models, to elucidate the molecular mechanisms underlying TREK-1-mediated protection. This work has the potential to establish TREK-1 signaling as a new ARDS pathway and highlight TREK-1 activation as a novel therapeutic target. The award period runs from August 16, 2024 through June 30, 2029.
Generated 1/28/25, 9:08 AM